- hiv infection - active hepatitis b infection - renal failure (crcl < 60 ml/min/1.73 m2) or need for hemodialysis - osteoporosis - myasthenia gravis - retinitis pigmentosa - bradycardia (less than 50 bpm) - weight less than 40 kg - treatment with drugs that prolong the qt interval for more than 7 days in the last month before randomization including: azithromycin, cisapride, methadone, droperidol, sotalol, quinidine, clarithromycin, haloperidol... - hereditary intolerance to galactose, lapp lactase deficiency or glucose or galactose malabsorption - treatment with fluvoxamine - treatment with benzodiazepines or benzodiazepine analogues such as zolpidem, zopiclone or zaleplon - pregnancy - breastfeeding - history of potentially immune derived diseases such as: lupus, crohn's disease, ulcerative colitis, vasculitis or rheumatoid arthritis - insulin-dependent diabetes mellitus - known history of hypersensitivity to the study drug or any of its components - patients that should not be included in the study at the judgment of the research team

- hiv infection - active hepatitis b infection - renal failure (crcl < 60 ml/min/1.73 m2) or need for hemodialysis - osteoporosis - myasthenia gravis - retinitis pigmentosa - bradycardia (less than 50 bpm) - weight less than 40 kg - treatment with drugs that prolong the qt interval for more than 7 days in the last month before randomization including: azithromycin, cisapride, methadone, droperidol, sotalol, quinidine, clarithromycin, haloperidol... - hereditary intolerance to galactose, lapp lactase deficiency or glucose or galactose malabsorption - treatment with fluvoxamine - treatment with benzodiazepines or benzodiazepine analogues such as zolpidem, zopiclone or zaleplon - pregnancy - breastfeeding - history of potentially immune derived diseases such as: lupus, crohn's disease, ulcerative colitis, vasculitis or rheumatoid arthritis - insulin-dependent diabetes mellitus - known history of hypersensitivity to the study drug or any of its components - patients that should not be included in the study at the judgment of the research team